Tukey RH, Strassburg CP. Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Annu Rev Pharmacol Toxicol. 2000;40:581–616.

Article  CAS  PubMed  Google Scholar 

US Food and Drug Administration: Guidance for industry: safety testing of drug metabolites (2020). https://www.fda.gov/regulatory-information/search-fda-guidance-documents/safety-testing-drug-metabolites. Accessed 21 Sep 2022.

Frances B, Gout R, Campistron G, Panconi E, Cros J. Morphine-6-glucuronide is more mu-selective and potent in analgesic tests than morphine. Prog Clin Biol Res. 1990;328:477–80.

CAS  PubMed  Google Scholar 

van Heek M, Farley C, Compton DS, Hoos L, Alton KB, Sybertz EJ, Davis HR Jr. Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663. Br J Pharmacol. 2000;129(8):1748–54.

Article  PubMed  PubMed Central  Google Scholar 

Faed EM. Properties of acyl glucuronides: implications for studies of the pharmacokinetics and metabolism of acidic drugs. Drug Metab Rev. 1984;15(5-6):1213–49.

Article  CAS  PubMed  Google Scholar 

Skonberg C, Olsen J, Madsen KG, Hansen SH, Grillo MP. Metabolic activation of carboxylic acids. Expert Opin Drug Metab Toxicol. 2008;4:425–38.

Article  CAS  PubMed  Google Scholar 

Bailey M, Dickinson RG. Acyl glucuronide reactivity in perspective: biological consequences. Chem Biol Interact. 2003;145(2):117–37.

Article  CAS  PubMed  Google Scholar 

Zhang Z. Bioanalysis of unstable analytes in generic drug review. Regulated Bioanalysis Workshop: Requirements and Expectations, June 30, 2020, Small Business and Industry Assistance. < https://sbiaevents.com/bioanalysis2020/> (2020). Accessed 21 Sep 2022.

Shipkova M, Armstrong VW, Oellerich M, Wieland E. Acyl glucuronide drug metabolites: toxicological and analytical implications. Ther Drug Monit. 2003;25:1–16.

Article  CAS  PubMed  Google Scholar 

Illing HP, Wilson ID. pH dependent formation of beta-glucuronidase resistant conjugates from the biosynthetic ester glucuronide of isoxepac. Biochem Pharmacol. 1981;30(24):3381–4.

Article  CAS  PubMed  Google Scholar 

Patel SR. Bioanalytical challenges and strategies for accurately measuring acyl glucuronide metabolites in biological fluids. Biomed Chromatogr. 2020;34(1):e4640.

Article  CAS  PubMed  Google Scholar 

Silvestro L, Gheorghe M, Iordachescu A, Ciuca V, Tudoroniu A, Savu SR, Tarcomnicu I. Development and validation of an HPLC–MS/MS method to quantify clopidogrel acyl glucuronide, clopidogrel acid metabolite, and clopidogrel in plasma samples avoiding analyte back-conversion. Anal Bioanal Chem. 2011;401(3):1023–34.

Article  CAS  PubMed  Google Scholar 

Sparidans RW, Lagas JS, Schinkel AH, Schellens JHM, Beijnen JH. Liquid chromatography–tandem mass spectrometric assay for diclofenac and three primary metabolites in mouse plasma. J Chromatogr B. 2008;872(1):77–82.

Article  CAS  Google Scholar 

Mullangi R, Bhamidipati RK, Srinivas NR. Bioanalytical aspects in characterization and quantification of glucuronide conjugates in various biological matrices. Curr Pharm Anal. 2005;1(3):251–64.

Article  CAS  Google Scholar 

Schwartz MS, Desai RB, Bi S, Miller AR, Matuszewski BK. Determination of a prostaglandin D2 antagonist and its acyl glucuronide metabolite in human plasma by high performance liquid chromatography with tandem mass spectrometric detection – a lack of MS/MS selectivity between a glucuronide conjugate and a Phase I metabolite. J Chromatogr B. 2006;837(1):116–24.

Article  CAS  Google Scholar 

Viswanathan CT, Bansal S, Booth B, DeStefano AJ, Rose MJ, Sailstad J, et al. Quantitative bioanalytical methods validation and implementation: best practices for chromatographic and ligand binding assays. Pharm Res. 2007;24(10):1962–73.

Article  CAS  PubMed  Google Scholar 

Subramaniam S, Stier E, Davit BM. Incurred sample reanalysis in bioequivalence studies for abbreviated new drug applications. Bioanalysis. 2014;6(24):3349–54.

Article  CAS  PubMed  Google Scholar 

Zhou J, Li F, Duggan JX. LC-MS bioanalysis of acyl glucuronides. In Handbook of LC-MS bioanalysis: best practices, Experimental Protocols, and Regulations, First Edition (eds. Li W, Zhang J, and Tse FLS) 447–460 (John Wiley & Sons, Inc., Philadelphia, 2013).

Montpetitm H, Ranger M, Colin P, Furtado M, Garofolo F. Discovery of a novel trimebutine metabolite and its impact on N-desmethyltrimebutine quantification by LC–MS/MS. Bioanalysis. 2015;7(8):1007–15.

Article  Google Scholar 

Camilleri P, Buch A, Soldo B, Hutt AJ. The influence of physicochemical properties on the reactivity and stability of acyl glucuronides. Xenobiotica. 2018;48(9):958–72.

Article  CAS  PubMed  Google Scholar 

FDA label for PRADAXA® (dabigatran etexilate) capsule, revised 6/2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/022512s041lbl.pdf. Accessed 21 Sep 2022.

FDA draft guidance on dabigatran etexilate mesylate capsule, recommended Jun 2012; revised Sep 2015, Jul 2017. https://www.accessdata.fda.gov/drugsatfda_docs/psg/Dabigatran%20etexilate%20mesylate_oral%20capsule_NDA%20022512_RV05-17.pdf. Accessed 21 Sep 2022.

Zhong S, Jones R, Lu W, Schadt S, Ottaviani G. A new rapid in vitro assay for assessing reactivity of acyl glucuronides. Drug Metab Dispos. 2015;43(11):1711–7.

Article  CAS  PubMed  Google Scholar 

Shipkova M, Armstrong VW, Schneider T, Niedmann PD, Schütz E, Wieland E, Oellerich M. Stability of mycophenolic acid and mycophenolic acid glucuronide in human plasma. Clin Chem. 1999;45(1):127–9.

Article  CAS  PubMed  Google Scholar 

US Food and Drug Administration: M10 bioanalytical method validation (2018) https://www.fda.gov/media/128343/download. Accessed 21 Sep 2022.